ALFA Finder| Revenue growth | 33.3% YoY; 11.2% QoQ. |
|---|---|
| Margins | EBITDA margin expanded to 30.0% from 26.6% YoY. |
| Demand visibility | Strong chronic therapy growth in India; complex generic pipeline in US. |
| Management confidence | High; citing market outperformance in India and US portfolio execution. |
Growth
Net Sales reached INR 82,172 mn (+33% YoY); EBITDA surged 50% YoY to INR 24,635 mn.
Outlook
Targeting 20+ complex product launches in India and 15+ US ANDA filings in FY27.
Risks
Pricing pressure in select US products (Mirabegron) and regulatory remediation ongoing at Pithampur Unit II and Mandideep.
Last quarter's promises, checked
Delivered
- Guided 27-28% EBITDA margin → delivered 29.7% (= BEAT)
- Guided 1.2x-1.3x IPM growth in India → delivered 1.1x (= BEAT)
- Guided 50+ US products in 3 years → launched 15 in FY26 (= BEAT)
Partly delivered
- Guided US business sustainability → delivered $1.3bn but noted mid-single digit price erosion (= PARTIAL)
Investor Presentation filed with NSE, NSE: LUPIN. Summary written with AI assistance from the document.
Lupin Ltd: key numbers
- Share price
- ₹2,023.40
- Market cap
- ₹92,529 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 17.8×Sector 43.8×
- Promoter holding
- 46.84%-0.01% QoQ
- FII holding
- 23.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lupin Ltd
All →Lupin Earnings Call Transcript: Key Takeaways
Revenue up 11% to ₹7,827 Cr, but EBITA margin fell to 25.1% from 31.3%; US down 13.4% QoQ on Tolvaptan erosion; management hedged FY28 outlook.
Lupin Investor Presentation: Key Takeaways
Q2 FY27 net sales ₹77,855mn (+14% YoY); EBITDA ₹19,574mn, margin 25.1% (vs 31.3%); net income ₹11,553mn (-21.8% YoY). US pressured by competition/LOE.
Lupin Management Change
Lupin appointed Akhil Gupta as an Additional and Independent Director effective 3 November 2026, for five years to 2031. The appointment is subject to shareholder approval.
Lupin Q2 FY27 Results: Net Profit ₹1,155 Cr, Down 22.2% YoY
Lupin Ltd reported revenue from operations of ₹7,827 Cr (+11.1% YoY) and net profit of ₹1,155 Cr (-22.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,155 Cr · -22.2% YoY
Lupin Product Launch
Lupin launched generic Raltegravir Tablets 600 mg in the United States. It is first-to-file, with 180-day exclusivity.
Lupin Regulatory Approval
Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.